Plasma is a composite mixture of more than 700 proteins and other substances which are vital for the smooth functioning of the human body. Plasma is the liquid component of blood, constituting around 50% of the total blood volume. Plasma in itself is approximately 90% water, with the remaining 10% comprising of proteins, minerals, clotting factors, hormones, and immunoglobins. Plasma is the raw material for the extraction of various proteins which are used for their therapeutic values. Plasma proteins cannot be manufactured rather the same are obtained or collected from a large pool of donors.
With the swift progression in the field of biomedical/healthcare technology, companies operating in the healthcare/pharmaceutical/therapeutic industry are now surmounting in the respective realm. Also, on account of the escalating incidences of health related issues originating due to changing lifestyle and continuously changing surroundings, blood plasma industry’s growth is augmented. In order to address the unmet medical needs related to blood disorders, autoimmune diseases and liver function impairment among others, associated companies are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma.
The blood plasma industry is highly regulated to ensure the safety of collected plasma and protect donors. The market is characterized by fast pace developments in the clinical technology and testing methodology. This report elicits the global blood plasma market with focus on segmental markets like IVIG, albumin and hemophilia market. Also the regions including the US and China are covered. Moreover, market dynamics like the key trends, industry developments, growth drivers and challenges are analyzed in detail.
Furthermore, the competitive landscape of the industry is highlighted. The rivalry prevalent in the global blood plasma market is quite fierce with numerous local and global players contenting for the market share. On the global front, the key players are Baxter, CSL, Grifols and Octapharma.